Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Mi Deng, Heyu Chen, Xiaoye Liu, et al.
Antibody Therapeutics (2021) Vol. 4, Iss. 1, pp. 16-33
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

The neuroimmune axis of Alzheimer’s disease
Mehdi Jorfi, Anna Maaser-Hecker, Rudolph E. Tanzi
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 170
Clinical landscape of macrophage-reprogramming cancer immunotherapies
Jenna H. Rannikko, Maija Hollmén
British Journal of Cancer (2024) Vol. 131, Iss. 4, pp. 627-640
Open Access | Times Cited: 17
CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response
Q. Cen, Jianyu Chen, Jiaxin Guo, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis
Guojin Wu, Yixiang Xu, Robbie D. Schultz, et al.
Nature Cancer (2021) Vol. 2, Iss. 11, pp. 1170-1184
Open Access | Times Cited: 43
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
Tobias Zeller, Ira A. Münnich, Roland Windisch, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Human leukocyte immunoglobulin-like receptors in health and disease
Silvia Redondo-García, Christopher Barritt, Charys Papagregoriou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Ben Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 4, pp. 471-484
Open Access | Times Cited: 15
Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells
Linheng Li, Roy A. Jensen
Cancer Research (2023) Vol. 83, Iss. 13, pp. 2096-2104
Open Access | Times Cited: 14
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Shira Tabachnick‐Cherny, Thomas H. Pulliam, Haroldo J. Rodriguez, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 6, pp. 1189-1199
Open Access | Times Cited: 13
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Miao Xian, Qiang Wang, Liuling Xiao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy
Calvin D. De Louche, Ali Roghanian
JCI Insight (2022) Vol. 7, Iss. 2
Open Access | Times Cited: 21
Blocking LAIR1 signaling in immune cells inhibits tumor development
Jingjing Xie, Xun Gui, Mi Deng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Targeting immune checkpoints on myeloid cells: current status and future directions
Chuhan Ma, Yang Li, Min Li, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
LILRB4 as a novel immunotherapeutic target for multiple diseases
Xu Wang, Lanying Li, Dan Liu, et al.
Biochemical Pharmacology (2025), pp. 116762-116762
Closed Access
Immune genes involved in synaptic plasticity during early postnatal brain development contribute to post-stroke damage in the aging male rat brain
Denisa Pîrșcoveanu, Denissa Greta Olaru, Dirk M. Hermann, et al.
Biogerontology (2025) Vol. 26, Iss. 2
Closed Access
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Ryan Huang, Xiaoye Liu, Jaehyup Kim, et al.
Cancer Immunology Research (2023) Vol. 12, Iss. 3, pp. 350-362
Open Access | Times Cited: 10
Functional insights into immunoglobulin superfamily proteins in invertebrate neurobiology and immunity
Hongyu Li, Yijie Zhang, Yunhuan Zhu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials
Chenchen Xu, Jiyu Chen, Mi Tan, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
ANGPTL8 is a negative regulator in pathological cardiac hypertrophy
Lin Hu, Jiarui Wei, Yue Zhang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 15
A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatment
Cheng Cheng Zhang
Biochemical and Biophysical Research Communications (2022) Vol. 633, pp. 64-67
Open Access | Times Cited: 15
Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma
Jing Fan, Jiayan Li, Jianbo Han, et al.
Molecular Immunology (2021) Vol. 136, pp. 82-97
Closed Access | Times Cited: 18
The prospect of tumor microenvironment-modulating therapeutical strategies
Dirk Eulberg, Anna Frömming, Kfir Lapid, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets
Joshua Morse, Margarita Ríos, John Ye, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 2, pp. 107-125
Open Access | Times Cited: 7
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 281-281
Open Access | Times Cited: 2
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
Pauline Schneider, Nicholas T. Crump, Susan T.C.J.M. Arentsen-Peters, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top